» Articles » PMID: 34012826

Factors Affecting Successful Use of Intranasal Dexmedetomidine: a Cohort Study from a National Paediatrics Tertiary Centre

Overview
Journal Transl Pediatr
Specialty Pediatrics
Date 2021 May 20
PMID 34012826
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Use of intranasal (IN) dexmedetomidine for procedural sedation has been reported in recent years. Good patient selection is important to ensure high success rates. We aimed to identify factors that influence the successful use of IN dexmedetomidine in non-invasive investigations.

Methods: All paediatric patients who received IN dexmedetomidine for investigations between 01 July 2019 to 01 July 2020 were included. Baseline demographics, time to reach adequate sedation level, duration of sedation, dose, indications for sedation and need for rescue sedatives were recorded. Procedures were classified into "long" or "short" according to completion time. Successful sedation was defined by completion of investigations by IN dexmedetomidine alone.

Results: Of 105 patients included, median age was 20.0 months, and median weight 11.0 kg. Magnetic resonance imaging (56, 53.3%) was the most common indication. Sixty (57.1%) were successfully sedated using IN dexmedetomidine alone. Automated auditory brainstem response, computerised tomography and mercaptoacetyltriglycine-3 renogram scans had the highest success rate (83.3%, 83.3%, and 100% respectively). On multivariate analysis, short procedures had an adjusted odds ratio of 5.30 (95% CI: 1.69-16.61; P=0.004) compared to long procedures.

Conclusions: IN dexmedetomidine is effective for procedural sedation for paediatric patients. The most important predictor for sedation success was indication of sedation and duration of procedures.

Citing Articles

Predictors of pediatric sedation failure with initial dose of intranasal dexmedetomidine and oral midazolam.

Cui Y, Gong T, Mu Q, Wu Q, Kang L, Chen Q Pediatr Res. 2023; 94(6):2054-2061.

PMID: 37507474 DOI: 10.1038/s41390-023-02758-0.


Sedation with Intranasal Dexmedetomidine in the Pediatric Population for Auditory Brainstem Response Testing: Review of the Existing Literature.

Marra P, Stadio A, Colacurcio V, Scarpa A, La Mantia I, Salzano F Healthcare (Basel). 2022; 10(2).

PMID: 35206901 PMC: 8872591. DOI: 10.3390/healthcare10020287.

References
1.
Haselkorn T, Whittemore A, Udaltsova N, Friedman G . Short-term chloral hydrate administration and cancer in humans. Drug Saf. 2006; 29(1):67-77. DOI: 10.2165/00002018-200629010-00005. View

2.
Li F, Wang X, Deng Z, Zhang X, Gao P, Liu H . Dexmedetomidine reduces oxidative stress and provides neuroprotection in a model of traumatic brain injury via the PGC-1α signaling pathway. Neuropeptides. 2018; 72:58-64. DOI: 10.1016/j.npep.2018.10.004. View

3.
Tug A, Hanci A, Turk H, Aybey F, Isil C, Sayin P . Comparison of Two Different Intranasal Doses of Dexmedetomidine in Children for Magnetic Resonance Imaging Sedation. Paediatr Drugs. 2015; 17(6):479-85. DOI: 10.1007/s40272-015-0145-1. View

4.
Wang Y, Han R, Zuo Z . Dexmedetomidine post-treatment induces neuroprotection via activation of extracellular signal-regulated kinase in rats with subarachnoid haemorrhage. Br J Anaesth. 2016; 116(3):384-92. PMC: 4748945. DOI: 10.1093/bja/aev549. View

5.
Sun R, Wang S, Li S, Yang C, Zhao Y, Luo A . Effects of dexmedetomidine on delirium and mortality during sedation in ICU patients: a systematic review and meta-analysis protocol. BMJ Open. 2019; 9(4):e025850. PMC: 6500184. DOI: 10.1136/bmjopen-2018-025850. View